Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Tipo del documento
País de afiliación
Intervalo de año de publicación
3.
Mikrobiyol Bul ; 46(1): 134-43, 2012 Jan.
Artículo en Turco | MEDLINE | ID: mdl-22399183

RESUMEN

Blastoschizomyces capitatus is a rare fungal pathogen that may lead to fatal infections especially in immunosuppressive individuals. In this report, three cases of B.capitatus were presented. The patients were under treatment for acute myeloid leukemia and their blood cultures yielded B.capitatus. The patients clinical conditions deteriorated and they died despite amphotericin B treatment. The isolates were identified by conventional mycological methods and API 20C AUX (Bio-Mérieux, France) system. Antifungal susceptibility test of the strains was performed with Sensititre Yeast One Panel (Trek Diagnostic Systems, USA) and minimum inhibitory concentration (MIC) ranges for amphotericin B, caspofungin, fluconazole, itraconazole, voriconazole, posaconazole, and flucytosine were found as 0.5-1; > 16; 8-16; 0.5; 0.25; 0.5-1 and 0.06-0.25 µg/ml, respectively. Isolated strains were genotyped with RAPD-PCR (Random Amplified Polymorphic DNA-Polymerase Chain Reaction) using Cnd-3, Cnd-4, OPE-03, OPE-18 primers. The strains isolated from the first two cases were found to be genotypically identical, while the strain isolated from the third case was different. Genotypically identical isolates belonged to two patients who were admitted to the hospital with approximately 18 months interval. The other strain with a unique genotype, was isolated from a patient who was admitted to the hospital about two years later than the other two patients. In conclusion, B.capitatus should be considered as an important opportunistic pathogen especially in patients with hematologic malignancies. The data of this study demonstrated that the lowest MIC values for B.capitatus strains were with voriconazole.


Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Fungemia/microbiología , Leucemia Mieloide Aguda/complicaciones , Saccharomycetales/aislamiento & purificación , Anfotericina B/farmacología , Antifúngicos/farmacología , Resultado Fatal , Femenino , Fungemia/tratamiento farmacológico , Genotipo , Humanos , Huésped Inmunocomprometido , Leucemia Mieloide Aguda/terapia , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Técnica del ADN Polimorfo Amplificado Aleatorio , Saccharomycetales/clasificación , Saccharomycetales/efectos de los fármacos , Saccharomycetales/genética
4.
Chemotherapy ; 50(3): 113-8, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15272225

RESUMEN

BACKGROUND: The pathophysiology of 5-fluorouracil (5-FU) cardiotoxicity is still controversial. The objective of this study was to assess the influence of high-dose leucovorin and infusional 5-FU regimen (HDLV5FU) on cardiac tissues. METHODS: We monitored 28 patients (median age 68 years) under HDLV5FU chemotherapy with complete blood counts, cardiac enzymes, C-reactive protein, coagulation tests, Holter electrocardiogram, and conventional echocardiography. Cardiac ultrasonic tissue characterization with integrated backscatter (IBS) analysis was performed in the 16 last enrolled patients. RESULTS: The magnitude of both anterior and posterior cardiac IBS values significantly decreased at the 48th hour of treatment compared to both 0th hour and day 15 (p < 0.003). Cardiac IBS values on the 15th day were not different from the 0th hour. Clinical cardiotoxicity was not observed and other monitored parameters did not change significantly in any patient (p > 0.5 for all). CONCLUSION: Cardiac IBS analysis suggests that 5-FU might cause reversible subclinical myocardial dysfunction.


Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Neoplasias Colorrectales/tratamiento farmacológico , Ecocardiografía/métodos , Fluorouracilo/efectos adversos , Corazón/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/uso terapéutico , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/diagnóstico por imagen , Quimioterapia Combinada , Electrocardiografía Ambulatoria , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/uso terapéutico , Corazón/fisiopatología , Humanos , Infusiones Intravenosas , Inyecciones Intravenosas , Leucovorina/administración & dosificación , Leucovorina/uso terapéutico , Masculino , Persona de Mediana Edad , Contracción Miocárdica/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA